Tan Kevin 4

What Happened

• Kevin Tan, CFO & Treasurer of Solid Biosciences (SLDB), was awarded 56,647 restricted stock units (RSUs) on January 29, 2026. The reported acquisition price is $0.00, indicating this is a compensation/performance award (derivative), not a purchase. The award reflects satisfaction of a performance milestone tied to a prior PSU grant; actual shares will only be issued if/when the RSUs vest.

Key Details

• Transaction date: 2026-01-29; reported on Form 4 filed 2026-04-21 (filed more than two business days after the transaction → appears late).
• Award type/code: A = Grant/Award (derivative RSUs); reported price $0.00.
• Shares awarded: 56,647 RSUs (each RSU represents a contingent right to one share upon vesting).
• Vesting/contingency: These stem from PSUs granted June 11, 2024. The Board determined the second performance milestone was met on Jan 29, 2026; related shares will vest only if the grantee remains in service on the Evaluation Date, anticipated in Q1 2027. Performance criteria are non-market, non-financial.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Filing timeliness: Form 4 was filed April 21, 2026 — more than two business days after the reported transaction date (i.e., late reporting).

Context

• This is a performance-based compensation award (not an open-market buy or sale). No cash was exchanged and no shares were immediately issued — the RSUs are contingent and subject to future vesting conditions (including continued service). Such awards are common for executives and do not by themselves indicate a buy or sell signal.